600488 津药药业
已收盘 11-29 15:00:00
资讯
新帖
简况
津药药业子公司获药品注册证书
财中社 · 11-28 19:00
津药药业子公司获药品注册证书
津药药业最新公告:子公司津药和平获得倍他米松磷酸钠注射液药品注册证书
证券之星 · 11-28 16:43
津药药业最新公告:子公司津药和平获得倍他米松磷酸钠注射液药品注册证书
津药药业:产品取得注册证
每日经济新闻 · 11-28 16:24
津药药业:产品取得注册证
津药药业(600488.SH)收到倍他米松磷酸钠注射液药品注册证书
智通财经 · 11-28 16:17
津药药业(600488.SH)收到倍他米松磷酸钠注射液药品注册证书
1-10月医保统筹收入稳增长,机构:医药后市反转源于三大机会
汇添富基金 · 11-28 08:11
1-10月医保统筹收入稳增长,机构:医药后市反转源于三大机会
津药药业最新公告:子公司湖北津药氯化钾注射液新增规格并通过一致性评价
证券之星 · 11-25
津药药业最新公告:子公司湖北津药氯化钾注射液新增规格并通过一致性评价
津药药业子公司氯化钾注射液获新规格批准
财中社 · 11-25
津药药业子公司氯化钾注射液获新规格批准
津药药业(600488.SH):氯化钾注射液通过仿制药一致性评价
智通财经网 · 11-25
津药药业(600488.SH):氯化钾注射液通过仿制药一致性评价
津药药业11月20日主力资金流入22万元 连续3日加仓
市场透视 · 11-20
津药药业11月20日主力资金流入22万元 连续3日加仓
津药药业:全球知名的甾体激素类药物生产企业 不断加快全球布局
投资快报 · 11-20
津药药业:全球知名的甾体激素类药物生产企业 不断加快全球布局
津药药业:截至2024年11月8日,公司股东数为42,803户
证券之星 · 11-11
津药药业:截至2024年11月8日,公司股东数为42,803户
津药药业子公司获批新增二羟丙茶碱注射液2ml:0.3g规格
财中社 · 11-08
津药药业子公司获批新增二羟丙茶碱注射液2ml:0.3g规格
津药药业最新公告:子公司药品新增规格及通过一致性评价
证券之星 · 11-08
津药药业最新公告:子公司药品新增规格及通过一致性评价
津药药业(600488.SH):二羟丙茶碱注射液新增规格并通过仿制药一致性评价
智通财经 · 11-08
津药药业(600488.SH):二羟丙茶碱注射液新增规格并通过仿制药一致性评价
津药药业:公司2022年建立财务共享中心,目前共享实施正处于初建期向提升期过渡阶段
证券之星 · 11-04
津药药业:公司2022年建立财务共享中心,目前共享实施正处于初建期向提升期过渡阶段
津药药业:截至2024年10月31日,公司股东数为42,285户
证券之星 · 11-01
津药药业:截至2024年10月31日,公司股东数为42,285户
津药药业第三季度净利润同比增长57.62% 药品研发成果不断
中国财富通 · 10-29
津药药业第三季度净利润同比增长57.62% 药品研发成果不断
津药药业(600488.SH)发前三季业绩,净利润1.87亿元,同比增长23.03%
智通财经 · 10-29
津药药业(600488.SH)发前三季业绩,净利润1.87亿元,同比增长23.03%
津药药业(600488)10月18日股东户数4.21万户,较上期增加0.06%
证券之星 · 10-29
津药药业(600488)10月18日股东户数4.21万户,较上期增加0.06%
津药药业:2024年前三季度净利润约1.87亿元
每日经济新闻 · 10-29
津药药业:2024年前三季度净利润约1.87亿元
加载更多
公司概况
公司名称:
津药药业股份有限公司
所属行业:
医药制造业
上市日期:
2001-06-18
主营业务:
津药药业股份有限公司主要从事皮质激素类、氨基酸类原料药及制剂的研发、生产和销售,公司主要产品地塞米松系列、泼尼松系列、甲泼尼龙系列、倍他米松系列、氨基酸原料药、片剂、小容量注射剂、软膏剂、乳膏剂、涂膜剂、凝胶剂、膜剂、栓剂、硬胶囊剂、丸剂、冻干粉针剂。公司多次获得中国化学制药协会 “国内原料药出口十强企业”称号。
发行价格:
11.25
{"stockData":{"symbol":"600488","market":"SH","secType":"STK","nameCN":"津药药业","latestPrice":4.6,"timestamp":1732863601000,"preClose":4.56,"halted":0,"volume":11729275,"delay":0,"floatShares":1092000000,"shares":1092000000,"eps":0.1393,"marketStatus":"已收盘","marketStatusCode":5,"change":0.04,"latestTime":"11-29 15:00:00","open":4.56,"high":4.7,"low":4.55,"amount":54105900,"amplitude":0.0329,"askPrice":4.61,"askSize":368,"bidPrice":4.6,"bidSize":207,"shortable":0,"etf":0,"ttmEps":0.1393,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1733103000000},"adr":0,"adjPreClose":4.56,"symbolType":"stock","openAndCloseTimeList":[[1732843800000,1732851000000],[1732856400000,1732863600000]],"highLimit":5.02,"lowLimit":4.1,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1091886680,"pbRate":1.65,"roa":"--","roe":"6.21%","epsLYR":0.107,"committee":-0.329627,"marketValue":5023000000,"floatMarketCap":5023000000,"peRate":33.022253,"changeRate":0.0088,"turnoverRate":0.0107,"status":0,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2024-12-02。"},"requestUrl":"/m/hq/s/600488","defaultTab":"news","newsList":[{"id":"2486139273","title":"津药药业子公司获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2486139273","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486139273?lang=zh_cn&edition=full","pubTime":"2024-11-28 19:00","pubTimestamp":1732791645,"startTime":"0","endTime":"0","summary":"公告中提到,公司子公司津药和平(天津)制药有限公司近日收到国家药品监督管理局颁发的倍他米松磷酸钠注射液的《药品注册证书》。自2023年1月津药和平向国家药品监督管理局提交该药品注册申请以来,累计投入研发费用约656万元。此次获得药品注册证书将有助于公司拓展国内制剂市场,提升业绩,但市场竞争和销售不确定性仍需投资者谨慎考虑。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241128192000a25c45de&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241128192000a25c45de&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0102","BK0028","BK0012","600488","BK0239"],"gpt_icon":0},{"id":"2486367886","title":"津药药业最新公告:子公司津药和平获得倍他米松磷酸钠注射液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2486367886","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486367886?lang=zh_cn&edition=full","pubTime":"2024-11-28 16:43","pubTimestamp":1732783427,"startTime":"0","endTime":"0","summary":"津药药业公告,子公司津药和平(天津)制药有限公司收到国家药品监督管理局核准签发的关于倍他米松磷酸钠注射液的《药品注册证书》。该药品主要用于过敏性与自身免疫性炎症性疾病,如活动性风湿病、类风湿性关节炎、红斑狼疮等。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112800025748.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","600488","BK0239","BK0012","BK0102"],"gpt_icon":0},{"id":"2486736238","title":"津药药业:产品取得注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2486736238","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486736238?lang=zh_cn&edition=full","pubTime":"2024-11-28 16:24","pubTimestamp":1732782267,"startTime":"0","endTime":"0","summary":"每经AI快讯,津药药业 11月28日晚间发布公告称,近日,津药药业股份有限公司子公司津药和平(天津)制药有限公司收到国家药品监督管理局核准签发的关于倍他米松磷酸钠注射液的《药品注册证书》。产品名称为“倍他米松磷酸钠注射液”。2024年1至6月份,津药药业的营业收入构成为:甾体激素类占比58.94%,制剂占比31.55%,氨基酸类原料药占比8.7%,其他业务占比0.77%。截至发稿,津药药业市值为50亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241128162610abe5591c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241128162610abe5591c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0028","BK0239","BK0012","BK0102","600488"],"gpt_icon":0},{"id":"2486610703","title":"津药药业(600488.SH)收到倍他米松磷酸钠注射液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2486610703","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486610703?lang=zh_cn&edition=full","pubTime":"2024-11-28 16:17","pubTimestamp":1732781848,"startTime":"0","endTime":"0","summary":"智通财经APP讯,津药药业(600488.SH)发布公告,公司子公司津药和平(天津)制药有限公司(简称“津药和平”)收到国家药品监督管理局核准签发的关于倍他米松磷酸钠注射液的《药品注册证书》。倍他米松磷酸钠注射液主要用于过敏性与自身免疫性炎症性疾病。现多用于活动性风湿病、类风湿性关节炎、红斑狼疮、严重支气管哮喘、严重皮炎、急性白血病等,也用于某些感染的综合治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1217190.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0239","BK0012","BK0102","600488"],"gpt_icon":0},{"id":"2486387128","title":"1-10月医保统筹收入稳增长,机构:医药后市反转源于三大机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2486387128","media":"汇添富基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486387128?lang=zh_cn&edition=full","pubTime":"2024-11-28 08:11","pubTimestamp":1732752682,"startTime":"0","endTime":"0","summary":"消息面上,据医保局日前披露,2024年1-10月医保统筹基金收入23065.07亿元,同比增长8.9%;2024年1-10月统筹支出19165.88亿元,同比增长8.9%。对此,国泰君安表示,1-10月医保统筹基金运行平稳,收入稳健增长,支出增速逐月收窄。国金证券表示,由于多方面因素,医药板块景气度在2021年后经历了长时间的下行。2024年11月7日,国家医保局召开了座谈会,强调了全国统一医保平台和大数据赋能商保发展的重要性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112807590598e4504f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112807590598e4504f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600129","688266","688177","600739","603108","600056","600200","600329","688443","600161","688176","603259","688247","BK0185","688626","601607","600332","605177","688180","688581","688617","600055","688139","688067","688382","688356","688046","688221","688690","600535","688488","688373","688192","688520","600196","688301","688117","603939","BK0096","600867","688166","BK0012","688189","688271","BK0188","605199","688321","688235","600851","603309","688336","688193","603367","688276","688198","688315","688062","603127","688389","688085","688351","688091","603658","688114","159938","603882","600521","600252","600211","600771","603456","603858","600380","600572","603087","688506","BK0239","603392","688076","688298","BK0028","688687","603590","603567","600080","688202","600976","688578","688278","600285","600079","603301","688105","688575","688670","688073","600062","600436","600276","603233","688566","600721","688212","600488","600351","688658","688428","688161","688029","688767","603538","600511","688163","688222","600566","600529","603896","600763","688050","603707","603439","600420","688137","600085","BK0070","688331","600422","600998","688656"],"gpt_icon":0},{"id":"2486772344","title":"津药药业最新公告:子公司湖北津药氯化钾注射液新增规格并通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2486772344","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486772344?lang=zh_cn&edition=full","pubTime":"2024-11-25 16:15","pubTimestamp":1732522507,"startTime":"0","endTime":"0","summary":"津药药业公告,其子公司湖北津药收到国家药品监督管理局核准签发的氯化钾注射液的《药品补充申请批准通知书》,批准本品新增规格及通过仿制药质量和疗效一致性评价。氯化钾注射液为国家医保(2023)甲类品种,用于治疗和预防低钾血症,适用于无法口服补钾时。湖北津药氯化钾注射液2008年首次取得国家药品监督管理局颁发的药品注册证书。截至目前,湖北津药在氯化钾注射液项目上已累计投入研发费用约557万元。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112500019638.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0012","BK0102","600488"],"gpt_icon":0},{"id":"2486742487","title":"津药药业子公司氯化钾注射液获新规格批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2486742487","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486742487?lang=zh_cn&edition=full","pubTime":"2024-11-25 15:55","pubTimestamp":1732521353,"startTime":"0","endTime":"0","summary":"公告指出,公司子公司湖北公司近日收到国家药品监督管理局核准的氯化钾注射液的《药品补充申请批准通知书》,批准该药品新增10ml:1.5g规格,并通过仿制药质量和疗效一致性评价。截至目前,湖北津药在氯化钾注射液项目上已累计投入研发费用约557万元。根据米内网数据,2022年和2023年氯化钾注射液的国内销售额分别为6.12亿元和6.61亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241125160912abdd3866&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241125160912abdd3866&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600488","BK0028","BK0012","BK0239","BK0102"],"gpt_icon":0},{"id":"2486776216","title":"津药药业(600488.SH):氯化钾注射液通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2486776216","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486776216?lang=zh_cn&edition=full","pubTime":"2024-11-25 15:32","pubTimestamp":1732519970,"startTime":"0","endTime":"0","summary":"津药药业(600488.SH)发布公告,公司子公司湖北津药药业股份有限公司(简称“...","market":"hk","thumbnail":"https://img.zhitongcaijing.com/astock/5.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/5.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1215278.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["600488","BK0102","BK0012","BK0028","BK0239"],"gpt_icon":0},{"id":"2484685241","title":"津药药业11月20日主力资金流入22万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2484685241","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484685241?lang=zh_cn&edition=full","pubTime":"2024-11-20 15:20","pubTimestamp":1732087245,"startTime":"0","endTime":"0","summary":"11月20日, 津药药业股价涨2.06%,报收4.45元,成交金额4308万元,换手率0.89%,振幅2.75%,量比1.11。津药药业今日主力资金净流入22万元,连续3日净流入,上一交易日主力净流入34万元,今日环比减少35.29%。该股近5个交易日上涨0.45%,主力资金累计净流出210万元;近20日主力资金累计净流入106万元,其中净流入天数为10日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120153522a247dc19&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120153522a247dc19&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0102","600488","BK0012","BK0028","BK0239"],"gpt_icon":0},{"id":"2484842922","title":"津药药业:全球知名的甾体激素类药物生产企业 不断加快全球布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2484842922","media":"投资快报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484842922?lang=zh_cn&edition=full","pubTime":"2024-11-20 00:13","pubTimestamp":1732032783,"startTime":"0","endTime":"0","summary":"公司一直积极实施以甾体激素类和氨基酸类药物为核心的原料药制剂一体化布局,在立足本土的同时不断加快全球布局。作为天津市科技领军企业,津药和平一直致力于成为国内甾体激素制剂药物研发和生产基地,近年来相继荣获国家高新技术企业、天津市企业技术中心、天津市技术领先型企业、天津市科技型企业、天津市先进外商投资企业、天津市绿色工厂等资质及荣誉称号。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120002135a2462207&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120002135a2462207&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0028","600488","BK0239","BK0012","BK0102"],"gpt_icon":0},{"id":"2482220551","title":"津药药业:截至2024年11月8日,公司股东数为42,803户","url":"https://stock-news.laohu8.com/highlight/detail?id=2482220551","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482220551?lang=zh_cn&edition=full","pubTime":"2024-11-11 18:00","pubTimestamp":1731319240,"startTime":"0","endTime":"0","summary":"证券之星消息,津药药业(600488)11月11日在投资者关系平台上答复投资者关心的问题。投资者:尊敬的董秘你好衷心感谢你们不厌其烦回答投资者的提问。请问贵公司2024年11月8日A股股东人数是多少?谢谢津药药业董秘:投资者您好!截至2024年11月8日,公司股东数为42,803户。感谢您的关注!以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111100023130.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","600488","BK0012","BK0102"],"gpt_icon":0},{"id":"2481312809","title":"津药药业子公司获批新增二羟丙茶碱注射液2ml:0.3g规格","url":"https://stock-news.laohu8.com/highlight/detail?id=2481312809","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481312809?lang=zh_cn&edition=full","pubTime":"2024-11-08 16:56","pubTimestamp":1731056181,"startTime":"0","endTime":"0","summary":"公告中提到,公司子公司津药和平(天津)制药有限公司收到国家药品监督管理局的批准,新增二羟丙茶碱注射液的2ml:0.3g规格,并通过仿制药质量和疗效一致性评价。此次申请于2023年9月提交,经过审查,获准后核发药品批准文号。截至目前,津药和平在该药品项目上已累计投入研发费用约1968万元。根据市场数据,二羟丙茶碱注射液在2022年和2023年的国内销售额分别为1.47亿元和2.41亿元。文章来源:财中社津药药业子公司获批新增二羟丙茶碱注射液2ml:0.3g规格","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108171946a223bf1d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108171946a223bf1d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0028","600488","BK0102","BK0239","BK0012"],"gpt_icon":0},{"id":"2481417561","title":"津药药业最新公告:子公司药品新增规格及通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2481417561","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481417561?lang=zh_cn&edition=full","pubTime":"2024-11-08 16:14","pubTimestamp":1731053648,"startTime":"0","endTime":"0","summary":"津药药业公告称,公司子公司津药和平(天津)制药有限公司收到国家药监局核准签发的二羟丙茶碱注射液的《药品补充申请批准通知书》,批准该药品新增规格及通过仿制药质量和疗效一致性评价。二羟丙茶碱注射液适用于支气管哮喘、喘息型支气管炎、阻塞性肺气肿等缓解喘息症状,临床使用广泛。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110800025832.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0102","BK0239","600488","BK0012","BK0028"],"gpt_icon":0},{"id":"2481456901","title":"津药药业(600488.SH):二羟丙茶碱注射液新增规格并通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2481456901","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481456901?lang=zh_cn&edition=full","pubTime":"2024-11-08 15:34","pubTimestamp":1731051277,"startTime":"0","endTime":"0","summary":"智通财经APP讯,津药药业(600488.SH)发布公告,公司子公司津药和平(天津)制药有限公司(简称“津药和平”)收到国家药品监督管理局核准签发的二羟丙茶碱注射液的《药品补充申请批准通知书》,批准本品新增规格2ml:0.3g及通过仿制药质量和疗效一致性评价。二羟丙茶碱注射液适用于支气管哮喘、喘息型支气管炎、阻塞性肺气肿等缓解喘息症状,临床使用广泛。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1208446.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600488","BK0028","BK0012","BK0239","BK0102"],"gpt_icon":0},{"id":"2480854377","title":"津药药业:公司2022年建立财务共享中心,目前共享实施正处于初建期向提升期过渡阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2480854377","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480854377?lang=zh_cn&edition=full","pubTime":"2024-11-04 18:00","pubTimestamp":1730714440,"startTime":"0","endTime":"0","summary":"证券之星消息,津药药业(600488)11月04日在投资者关系平台上答复投资者关心的问题。投资者:请问贵公司的财务共享中心哪一年开始上线运行的,各类报告中并没有披露,想了解一下贵公司的财务数字化转型进程。谢谢!津药药业董秘:投资者您好!公司2022年建立财务共享中心,目前共享实施正处于初建期向提升期过渡阶段。未来,公司将不断强化数字化管理能力,根据业务发展需要积极推进财务数字化工作,提升财务管理水平。感谢您的关注!以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110400025119.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0239","600488","BK0028","BK0102"],"gpt_icon":0},{"id":"2480070899","title":"津药药业:截至2024年10月31日,公司股东数为42,285户","url":"https://stock-news.laohu8.com/highlight/detail?id=2480070899","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480070899?lang=zh_cn&edition=full","pubTime":"2024-11-01 18:00","pubTimestamp":1730455220,"startTime":"0","endTime":"0","summary":"证券之星消息,津药药业(600488)11月01日在投资者关系平台上答复投资者关心的问题。投资者:尊敬的董秘你好衷心感谢你们不厌其烦回答投资者的提问。请问贵公司2024年10月31日A股股东人数是多少?谢谢津药药业董秘:答:投资者您好!截至2024年10月31日,公司股东数为42,285户。感谢您的关注!以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110100036226.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600488","BK0239","BK0102","BK0012","BK0028"],"gpt_icon":0},{"id":"2479404743","title":"津药药业第三季度净利润同比增长57.62% 药品研发成果不断","url":"https://stock-news.laohu8.com/highlight/detail?id=2479404743","media":"中国财富通","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479404743?lang=zh_cn&edition=full","pubTime":"2024-10-29 20:39","pubTimestamp":1730205580,"startTime":"0","endTime":"0","summary":"10月29日晚间,津药药业发布2024年第三季度报告。公司第三季度实现营业收入约7.71亿元,实现归母净利润约0.45亿元,同比增长57.62%。三季度药品研发创新提速第三季度,津药药业及子公司研发取得瞩目成果。这离不开公司重视研发,大力推进研发工作,津药药业前三季度研发投入达1.36亿元,同比增长8.73%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://irb.cfbond.com/api/v1/detail.html?newsid=e5WIji4HXXM%3D","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["600488"],"gpt_icon":0},{"id":"2479479985","title":"津药药业(600488.SH)发前三季业绩,净利润1.87亿元,同比增长23.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479479985","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479479985?lang=zh_cn&edition=full","pubTime":"2024-10-29 18:11","pubTimestamp":1730196697,"startTime":"0","endTime":"0","summary":"智通财经APP讯,津药药业(600488.SH)发布2024年前三季度报告,报告期内公司实现营业收入25.72亿元,同比减少9.36%;归属于上市公司股东的净利润1.87亿元,同比增长23.03%;归属于上市公司股东扣除非经常性损益净利润1.84亿元,同比增长27.30%;基本每股收益0.171元/股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1202572.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600488"],"gpt_icon":0},{"id":"2479803427","title":"津药药业(600488)10月18日股东户数4.21万户,较上期增加0.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479803427","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479803427?lang=zh_cn&edition=full","pubTime":"2024-10-29 17:02","pubTimestamp":1730192560,"startTime":"0","endTime":"0","summary":"证券之星消息,近日津药药业披露,截至2024年10月18日公司股东户数为4.21万户,较10月10日增加27.0户,增幅为0.06%。在化学制药行业个股中,津药药业股东户数高于行业平均水平,截至10月18日,化学制药行业平均股东户数为3.11万户。从股价来看,2024年10月10日至2024年10月18日,津药药业区间跌幅为3.74%,在此期间股东户数增加27.0户,增幅为0.06%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102900029932.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0102","BK0028","BK0012","600488","BK0239"],"gpt_icon":0},{"id":"2479245854","title":"津药药业:2024年前三季度净利润约1.87亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2479245854","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479245854?lang=zh_cn&edition=full","pubTime":"2024-10-29 16:37","pubTimestamp":1730191053,"startTime":"0","endTime":"0","summary":"每经AI快讯,津药药业(SH 600488,收盘价:4.33元)10月29日晚间发布三季度业绩公告称,2024年前三季度营收约25.72亿元,同比减少9.36%;归属于上市公司股东的净利润约1.87亿元,同比增加23.03%;基本每股收益0.171元,同比增加23.02%。截至发稿,津药药业市值为47亿元。道达号(daoda1997)“个股趋势”提醒:1. 近30日内无机构对津药药业进行调研。每经头条(nbdtoutiao)——华尔街力挺,白银“王者归来”,价格创12年来新高!是否将继续“补涨”?个人投资者如何操作?(记者 蔡鼎)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241029163816a1f4b5a1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241029163816a1f4b5a1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600488"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2001-06-18","address":"天津市东丽区开发区西区新业九街19号","stockEarnings":[{"period":"1week","weight":0.0526},{"period":"1month","weight":0.0723},{"period":"3month","weight":0.2202},{"period":"6month","weight":0.192},{"period":"1year","weight":-0.1133},{"period":"ytd","weight":-0.0391}],"companyName":"津药药业股份有限公司","boardCode":"AI0027","perCapita":"25631股","boardName":"医药制造业","registeredCapital":"109188万元","compareEarnings":[{"period":"1week","weight":0.0181},{"period":"1month","weight":0.0184},{"period":"3month","weight":0.1704},{"period":"6month","weight":0.0776},{"period":"1year","weight":0.098},{"period":"ytd","weight":0.1182}],"survey":" 津药药业股份有限公司主要从事皮质激素类、氨基酸类原料药及制剂的研发、生产和销售,公司主要产品地塞米松系列、泼尼松系列、甲泼尼龙系列、倍他米松系列、氨基酸原料药、片剂、小容量注射剂、软膏剂、乳膏剂、涂膜剂、凝胶剂、膜剂、栓剂、硬胶囊剂、丸剂、冻干粉针剂。公司多次获得中国化学制药协会 “国内原料药出口十强企业”称号。","serverTime":1732956681162,"listedPrice":11.25,"stockholders":"42600人(较上一季度减少0.47%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"津药药业(600488)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供津药药业(600488)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"津药药业,600488,津药药业股票,津药药业股票老虎,津药药业股票老虎国际,津药药业行情,津药药业股票行情,津药药业股价,津药药业股市,津药药业股票价格,津药药业股票交易,津药药业股票购买,津药药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"津药药业(600488)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供津药药业(600488)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}